Navigation Links
MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy

BOTHELL, WA – June 25 – MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for inflammatory and infectious diseases, today announced the completion of its confirmatory phase III study of Vascana – a topical formulation designed to treat Raynaud’s Disease.

The study met its primary end point and demonstrated statistical significance, with p = 0.008 for the Intent-to-Treat patient population. Typically, a probability value (p) less than .05 is commonly accepted as establishing statistical significance between treatment groups.

“With the conclusion of this clinical study, MediQuest is one step closer to submitting the Vascana New Drug Application to the FDA,” said MediQuest President and CEO Dr. Frederick Dechow. “If approved, Vascana would be the first drug on the market specifically designed to prevent and treat Raynaud’s symptoms, providing clinicians with a needed treatment for patients.”

Vascana has the potential of satisfying an unmet medical need for more than 2 million Americans seeking care for Raynaud’s Disease.

In addition to Vascana, MediQuest’s ongoing developmental efforts have generated a robust pipeline that includes three drug candidates in clinical trials, one at the pre-clinical stage and others at the research stage. The company develops first- and best-in-class topical therapies to treat patients suffering from inflammatory and infectious diseases.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprietary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company’s major efforts are focused on projects targeting Raynaud’s phenomenon, nail psoriasis and actinic keratosis.

In addition to his
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:2/27/2015)... Feb. 27, 2015 Roughly three-quarters of ... confident substituting an interchangeable biosimilar for its branded ... same nonproprietary name, according to a survey published ... Journal of Managed Care & Specialty Pharmacy ... percent of pharmacists would feel as confident if ...
(Date:2/27/2015)... Feb. 27, 2015 The role of the ... but one thing hasn,t changed: face-to-face meetings are seen ... with Key Opinion Leaders. Yet at the ... valuable type of interaction, field medical teams within the ... interactions. This is just one of the challenges addressed ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015  Pomerantz ... Vitae Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com ... whether Vitae and certain of its officers and/or directors ... Exchange Act of 1934.  On February ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2
... and LYNBROOK, N.Y., Aug. 31, 2011 Auxilium Pharmaceuticals, ... company, and BioSpecifics Technologies Corp. (NASDAQ: BSTC ... dismissed all pending litigation between the Companies and announced ... cellulite and human and canine lipoma as well as ...
... 31, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... Torley, M.B. Ch. B., M.R.C.P.,  as Executive Vice President ... will report to N. Anthony Coles, M.D., President and ... commercial activities related to Nexavar and the potential launch ...
Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3
(Date:2/28/2015)... “Solutionman” Haman surveyed over 10,000 people to discover what ... “The #1 block was lack of time and the ... created the Thinkubator Innovation Studio in Chicago. Statistics ... not have enough time for innovative thinking and 41% ... Solutionman’s monthly “Accelerating Innovation Training” workshops address the “lack ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... 28, 2015 Vancouver personal injury lawyers at ... are affected by time limits. They stated that in many ... claim or even nullify it. Many a time, delays in ... client’s rights under BC law. As a result, experts at ... accidents should consult a personal injury lawyer in order to ...
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
Breaking Medicine News(10 mins):Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... linked to iron deficiency, intravenous administration of iron increases ... says a Turkish study. ,Since oral iron replacement ... first choice for treatment for iron-deficiency anemia, Dr. Ragip ... it seems that intravenous iron sucrose is a safe ...
... 'small is good' and those small portions help us keep over ... pour 20-30% more alcohol // into short , wide glasses than ... believe that tall glasses hold more. The study finds mention ... public but seasoned and professional bartenders do the same mistake or ...
... of Jharkhand has given health the status of industry. ... to receive all facilities provided under the industrial policy. ... and infrastructure support. ,The government move is ... the health sector in state, where half the population ...
... Woods with other scientists from British Cardiac Society, ... the Primary Care Cardiovascular Society // and ... preventing cardiovascular risks of heart attacks, stroke and ... drafted to reduce the risk of developing heart ...
... of Medicine in St. Louis has found that survivors of ... as depressed as some studies make them out to be ... December issue of Supportive Care in Cancer. ,This study ... Center at Washington University School of Medicine and Barnes-Jewish Hospital. ...
... in the December 21 issue of the Journal of the ... radiation reduces the ability // to repair the chromosomal damage ... developing basal cell carcinoma and squamous cell carcinoma. ... is responsible for breaking DNA strands in exposed skin cells. ...
Cached Medicine News:Health News:Intravenous Iron treats anemia of pregnancy faster 2
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
The MICROsed-System is the ideal system back up support to be used as front-line instrument with small workloads....
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: